方法：将符合纳入标准，经吲哚青绿脉络膜血管造影(indocyanine green angiography， ICGA)、光学相干断层扫描(optical coherence tomography， OCT)检查确诊为黄斑区脉络膜新生血管(CNV)患者27例27眼，经PDT治疗后3～7d内行ranibizumab玻璃体腔注射。观察治疗后1，3，6mo、末次随访时行最佳矫正视力、FFA、ICGA、OCT检查及有无并发症发生情况。

结果：最佳矫正视力提高17眼(63%)，最佳矫正视力稳定6眼(22%)，最佳矫正视力下降4眼(15%)。27例27眼治疗前平均渗漏面积为1 005.69±105.47μm，治疗后1，3mo后平均875.54±103.27，423.37±79.68μm，与治疗前比较差异有统计学意义(P<0.01)， 视网膜黄斑中央厚度27例27眼治疗前平均厚度为485.58±122.59μm，治疗后1，3mo后平均398.84±105.32，297.74±89.18μm，与治疗前比较差异有统计学意义(P<0.01)。

结论：PDT封闭CNV后，联合玻璃体内腔内注射ranibizumab，有效阻断新生血管复发，减少PDT再次治疗次数和并发症，可提高治疗效果。

METHODS: In accordance with the inclusion criteria, by indocyanine green choroidalangiography(ICGA)and optical coherence tomography(OCT)examination confirmed the diagnosis of macular CNV in 27 patients(27 eyes), treated with PDT 3～7d professional intravitreal injection of ranibizumab. At 1, 3, 6mo after treatment, the results of best corrected visual acuity(BCVA), FFA, ICGA, OCT examination and complications were observed.

RESULTS: The BCVA improved in 17 eyes(63%), stable in 6 eyes(22%), and decreased in 4 eyes(15%). Before treatment, the average leakage area was 1 005.69±105.47μm, it were 875.54±103.27μm, and 423.37±79.68μm at 1 and 3mo after treatment, there were significant differences compared with before treatment(P<0.01). Average central macular thickness of retina before treatment was 485.58±122.59μm, and 398.84±105.32μm, 297.74±89.18μ m at 1 and 3mo after treatment, there were significant differences compared with before treatment(P<0.01).

CONCLUSION: The method that PDT closed CNV combined with intravitreal injection of ranibizumab can effectively block angiogenesis recurrence, reduce the number of PDT treatment again and complications, improve the therapeutic effect.